Here are our best photos of 2019
National Geographic’s 100 best images of the year–curated from 106 photographers, 121 stories, and more than two million photographs.
Related Articles
Belief BioMed and Takeda China jointly announced BBM-H901 (Dalnacogene Ponparvovec Injection), China’s first hemophilia B gene therapy, was officially approved
/PRNewswire/ — Belief BioMed (“BBM”) and Takeda China today jointly announced that BBM-H901 (generic name: Dalnacogene Ponparvovec Injection), has been…
Generative AI in Medicine — Evaluating Progress and Challenges | NEJM
The National Academy of Medicine convened a workshop of experts and published a report that reviews the progress generative AI has achieved in health care…
Gene Therapy for Hemophilia – From Basic Science to First Approvals of “One-and-Done” Therapies
Over a period of nearly 3 decades, gene therapy for the inherited bleeding disorder hemophilia progressed from basic science to approval of 3 gene therapy…
FDA Approves Novel Treatment for Hemophilia A or B, with or without Factor Inhibitors
Today, the FDA approved a novel treatment for hemophilia A or B, with or without factor VIII or IX inhibitors (neutralizing antibodies).
The Limbic
the limbic is an editorially independent publication for healthcare professionals. It delivers the latest news and expert insight relevant to your specialty in an easy…
Induction of factor VIII tolerance by hemophilia gene transfer to eradicate factor VIII inhibitors
Abstract. Patients with hemophilia A can develop antifactor antibodies to factor VIII. The incidence is ∼30%, and such patients suffer worse morbidity and
NICE approves groundbreaking one-off gene therapy for severe sickle cell disease
People in England to benefit from groundbreaking one-off gene therapy for severe sickle cell disease approved by NICE
Andexanet alfa: trials just leave us with more questions
ANNEXA-I, the first ever randomised controlled trial of a reversal agent for direct oral anticoagulants, was published in 2024. The trial, which randomised patients with…
Andexanet alfa: trials just leave us with more questions
ANNEXA-I, the first ever randomised controlled trial of a reversal agent for direct oral anticoagulants, was published in 2024. The trial, which randomised patients with…